Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 13/20 | 0.70 |
| ▸ | MMP12 | P39900 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | SLC27A2 | O14975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14756569 | 0.90 | ADAMTS5 (0.71) | ADAMTS5MMP12MAPTLMNATP53 | |
| SCHEMBL15928247 | 0.89 | ADAMTS5 (0.78) | ADAMTS5MMP12MAPTLMNATP53 | |
| SCHEMBL18644811 | 0.86 | ADAMTS5 (0.66) | ADAMTS5MMP12MAPTLMNAMEN1 | |
| SCHEMBL14747047 | 0.85 | ADAMTS5 (0.68) | ADAMTS5MMP12MAPTLMNAMEN1 | |
| SCHEMBL14756576 | 0.85 | ADAMTS5 (0.62) | ADAMTS5MMP12LMNATP53MEN1 | |
| SCHEMBL14756565 | 0.85 | ADAMTS5 (0.69) | ADAMTS5MMP12MAPTLMNAMEN1 | |
| SCHEMBL29429414 | 0.83 | ADAMTS5 (0.64) | ADAMTS5MMP12MAPTLMNATP53 | |
| SCHEMBL6278160 | 0.83 | ADAMTS5 (0.64) | ADAMTS5MMP12MAPTLMNATP53 | |
| SCHEMBL14744656 | 0.83 | ADAMTS5 (0.64) | ADAMTS5MMP12MAPTLMNATP53 | |
| SCHEMBL4356155 | 0.82 | ADAMTS5 (1.00) | ADAMTS5MMP12SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598441-B2 | Therapeutic compounds and methods | WAYNE STATE UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598441-B2 | Therapeutic compounds and methods | WAYNE STATE UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2013033392-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | XPOT, FANCI, XPO5 | ADAMTS5 712/4885MMP12 3102/4885MAPT 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.